{"product_id":"cjc-1295-no-dac-ipamorelin-5mg-10mg-pen","title":"CJC-1295 (No DAC) + Ipamorelin | 15 Mg Pen","description":"\u003cp\u003e\u003cstrong\u003eCJC-1295 (No-DAC) + Ipamorelin\u003c\/strong\u003e is a blend positioned for controlled research settings where \u003cstrong\u003eendogenous GH-axis modulation\u003c\/strong\u003e is being studied in relation to \u003cstrong\u003epulsatile growth hormone dynamics, IGF-1 axis outputs, and metabolic adaptation endpoints\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSupports\u003c\/strong\u003e\u003c\/p\u003e\n\u003col\u003e\n\u003cli\u003ePhysiologic GH pulse amplification (pattern- and timing-dependent)\u003c\/li\u003e\n\u003cli\u003eDownstream IGF-1 and IGF-binding protein profiles (endpoint-based)\u003c\/li\u003e\n\u003cli\u003ePituitary GHRH-receptor signaling readouts (cAMP\/PKA-linked)\u003c\/li\u003e\n\u003cli\u003eGhrelin receptor (GHS-R1a)–mediated secretagogue signaling (calcium\/PKC-linked)\u003c\/li\u003e\n\u003cli\u003eBody-composition and substrate-utilization endpoints tracked in GH-secretagogue research\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003ch2\u003eDescription\u003c\/h2\u003e\n\u003cp\u003eCJC-1295 (No-DAC) + Ipamorelin combines two mechanistically distinct GH secretagogue approaches: a short-acting GHRH-analog pathway (CJC-1295 No-DAC) and a selective ghrelin receptor (GHS-R1a) agonist pathway (Ipamorelin). In experimental endocrinology, pairing these mechanisms is used to study whether dual-receptor stimulation can increase GH pulse amplitude while preserving rhythmic features that are central to physiologic GH signaling.\u003c\/p\u003e\n\u003cp\u003eIn research designs, CJC-1295 (No-DAC) is commonly positioned as a pulse-aligned stimulus acting at pituitary somatotroph GHRH receptors, while Ipamorelin is used to probe ghrelin-receptor secretagogue signaling with comparatively reduced emphasis on broader neuroendocrine effects described for some earlier GHRP compounds. Together, the blend is investigated through measurable endpoints such as GH pulsatility metrics, IGF-1\/IGFBP profiles, and metabolic or recovery-associated readouts where GH–IGF signaling is treated as a study variable.\u003c\/p\u003e\n\u003cp\u003eThis product is positioned strictly for laboratory research where endocrine outputs are monitored in controlled protocols and interpreted as model-dependent signals rather than therapeutic outcomes.\u003c\/p\u003e\n\u003ch2\u003eClinical Status\u003c\/h2\u003e\n\u003cp\u003eHuman research exists for GHRH analogs and GH secretagogues (including long-acting CJC-1295 constructs in controlled trials and ghrelin-receptor agonist programs), with extensive supporting preclinical and in vitro evidence describing receptor biology and downstream signaling. Evidence for a specific fixed-dose combination is typically interpreted through the broader class literature and mechanistic rationale rather than regulatory authorization.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEvidence type:\u003c\/strong\u003e\u003cbr\u003eHuman RCT ✔ | Observational ✔ | Animal ✔ | In vitro ✔ | Regulatory approval ☐\u003c\/p\u003e\n\u003ch2\u003eMechanism of Action\u003c\/h2\u003e\n\u003cp\u003eCJC-1295 (No-DAC) is studied as a GHRH-receptor agonist at anterior pituitary somatotroph cells. GHRH receptor activation increases adenylate cyclase activity and intracellular cAMP, engaging PKA-linked signaling that supports GH synthesis and release. The “No-DAC” designation is used to emphasize shorter systemic activity relative to albumin-binding (DAC) constructs, supporting timing-focused experiments on pulse architecture.\u003c\/p\u003e\n\u003cp\u003eIpamorelin is studied as a selective agonist at the ghrelin receptor (GHS-R1a), a GPCR involved in GH secretagogue signaling. In experimental systems, GHS-R1a activation is associated with intracellular calcium mobilization and downstream kinase signaling that can augment GH release. Dual stimulation (GHRH receptor + GHS-R1a) is used in research to examine additive or synergistic effects on GH pulse amplitude and consequent IGF-1 axis outputs, while keeping hypothalamic feedback dynamics measurable within the study design.\u003c\/p\u003e\n\u003ch2\u003eBenefits\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cb\u003eSynergistic Growth Hormone Stimulation\u003c\/b\u003e:\u003cbr\u003eThe combination of\u003cspan\u003e \u003c\/span\u003e\u003cb\u003eCJC-1295 (No-DAC) and Ipamorelin\u003c\/b\u003e\u003cspan\u003e \u003c\/span\u003eis studied for its\u003cspan\u003e \u003c\/span\u003e\u003cb\u003esynergistic activation of the pituitary growth hormone (GH) axis\u003c\/b\u003e. CJC-1295 (No-DAC) enhances natural GH-releasing hormone signaling, while Ipamorelin acts as a selective ghrelin receptor agonist. Together, they amplify pulsatile GH secretion, leading to increased IGF-1 levels and broad systemic support for tissue repair, recovery, and metabolism in research models.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eEnhanced Muscle Growth and Recovery\u003c\/b\u003e:\u003cbr\u003eThis peptide pairing has been observed to\u003cspan\u003e \u003c\/span\u003e\u003cb\u003esupport lean muscle development\u003c\/b\u003e\u003cspan\u003e \u003c\/span\u003ethrough improved nitrogen retention, protein synthesis, and satellite cell activation. The GH-IGF-1 cascade activated by this combination enhances muscle fiber repair and post-exercise recovery, making it highly relevant in regenerative and performance-related studies.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eImproved Sleep and Cellular Regeneration\u003c\/b\u003e:\u003cbr\u003eResearch shows that CJC-1295 + Ipamorelin enhances\u003cspan\u003e \u003c\/span\u003e\u003cb\u003edeep sleep quality\u003c\/b\u003e\u003cspan\u003e \u003c\/span\u003eby increasing natural GH pulses during the night. These nocturnal GH peaks are associated with accelerated cellular repair, collagen production, and improved recovery capacity — all critical factors for tissue restoration and long-term metabolic health.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eReduction of Adipose Tissue and Fat Oxidation\u003c\/b\u003e:\u003cbr\u003eThrough its influence on growth hormone signaling, this peptide combination stimulates\u003cspan\u003e \u003c\/span\u003e\u003cb\u003elipolysis and fatty acid mobilization\u003c\/b\u003e\u003cspan\u003e \u003c\/span\u003ewhile inhibiting lipogenesis. This metabolic rebalancing supports reduced body fat levels and improved body composition without altering appetite or blood glucose, highlighting its value in body recomposition and metabolic optimization research.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eIncreased Collagen Production and Skin Quality\u003c\/b\u003e:\u003cbr\u003eThe GH-IGF-1 axis stimulated by CJC-1295 + Ipamorelin promotes\u003cspan\u003e \u003c\/span\u003e\u003cb\u003ecollagen synthesis and skin elasticity\u003c\/b\u003e. Studies suggest improved dermal thickness and hydration, positioning this combination as a promising model for research into anti-aging and regenerative dermatology.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eSupport for Bone Density and Joint Integrity\u003c\/b\u003e:\u003cbr\u003eGrowth hormone pulses initiated by this combination stimulate\u003cspan\u003e \u003c\/span\u003e\u003cb\u003eosteoblastic activity and calcium retention\u003c\/b\u003e, improving bone mineral density and supporting joint health. The resulting enhancement of connective tissue integrity makes it a key focus in musculoskeletal regeneration and aging-related bone metabolism research.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eImproved Energy, Mood, and Cognitive Function\u003c\/b\u003e:\u003cbr\u003eBy modulating GH and IGF-1 signaling, this combination has been observed to\u003cspan\u003e \u003c\/span\u003e\u003cb\u003eimprove mental clarity, focus, and overall well-being\u003c\/b\u003e. The enhanced mitochondrial energy production associated with GH stimulation contributes to better vitality, motivation, and cognitive performance under metabolic stress conditions.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eRestoration of Hormonal Rhythm and Homeostasis\u003c\/b\u003e:\u003cbr\u003eCJC-1295 (No-DAC) + Ipamorelin is studied for its ability to\u003cspan\u003e \u003c\/span\u003e\u003cb\u003erestore natural GH pulsatility\u003c\/b\u003e\u003cspan\u003e \u003c\/span\u003ethat typically declines with age. This restoration supports circadian alignment, balanced endocrine output, and rejuvenated cellular function, providing a physiological approach to age-related hormonal decline models.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eEnhanced Recovery from Injury and Physical Stress\u003c\/b\u003e:\u003cbr\u003eThrough its regenerative effects on muscle, tendon, and joint tissues, this combination enhances\u003cspan\u003e \u003c\/span\u003e\u003cb\u003ehealing and recovery rates\u003c\/b\u003e\u003cspan\u003e \u003c\/span\u003efollowing physical strain or injury. The GH-mediated increase in collagen formation, cellular proliferation, and angiogenesis contributes to faster restoration of function in experimental recovery settings.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eImproved Metabolic Efficiency and Body Composition\u003c\/b\u003e:\u003cbr\u003eStudies indicate that GH secretagogues like CJC-1295 and Ipamorelin\u003cspan\u003e \u003c\/span\u003e\u003cb\u003eenhance basal metabolic rate and nutrient utilization\u003c\/b\u003e. This effect supports improved fat-to-muscle ratio, increased energy levels, and more efficient metabolic activity, making it a promising subject in obesity, longevity, and metabolic optimization research.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eSynergistic Longevity and Anti-Aging Potential\u003c\/b\u003e:\u003cbr\u003eBy sustaining GH-IGF-1 signaling and improving mitochondrial function, this combination supports\u003cspan\u003e \u003c\/span\u003e\u003cb\u003ecellular rejuvenation and longevity pathways\u003c\/b\u003e. When combined with peptides such as MOTS-c, SS-31, or NAD+, it offers a comprehensive research model for studying anti-aging mechanisms, mitochondrial protection, and energy system preservation.\u003c\/li\u003e\n\u003cli\u003e\u003cbr\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eResearch Data\u003c\/h2\u003e\n\u003ctable style=\"width: 100%; border-collapse: collapse;\" cellpadding=\"10\" cellspacing=\"0\" border=\"1\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eStudy\/model\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eReported effect\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePituitary somatotroph assays (GHRH receptor activation; in vitro)\u003c\/td\u003e\n\u003ctd\u003eIncreased GH release and cAMP-linked signaling readouts under GHRH-analog stimulation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGhrelin receptor (GHS-R1a) agonist assays (in vitro)\u003c\/td\u003e\n\u003ctd\u003eEnhanced secretagogue signaling with calcium-mobilization endpoints and GH release readouts\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCJC-1295 class trials in healthy adults (randomized, placebo-controlled)\u003c\/td\u003e\n\u003ctd\u003eIncreased GH and IGF-1 outputs with structured safety monitoring (class reference for GHRH analogs)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePulsatility analyses during GHRH-analog stimulation (human endocrine research)\u003c\/td\u003e\n\u003ctd\u003eGH pulses persist under stimulation; pulse architecture can be quantified as a primary endpoint\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eComparative GHRP\/ghrelin-agonist programs (human and preclinical)\u003c\/td\u003e\n\u003ctd\u003eSecretagogue effects on GH with protocol-dependent differences across compounds; endocrine markers tracked\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNeuroendocrine feedback frameworks (hypothalamic–pituitary modeling)\u003c\/td\u003e\n\u003ctd\u003eSomatostatin\/GHRH balance influences observed GH patterns; feedback-intact interpretation emphasized\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetabolic research contexts tracking GH–IGF outputs\u003c\/td\u003e\n\u003ctd\u003eChanges in body-composition and metabolic endpoints evaluated alongside GH\/IGF markers (population- and protocol-dependent)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCombination rationale (dual-receptor experimental design)\u003c\/td\u003e\n\u003ctd\u003eAdditive GH pulse amplitude effects are hypothesized\/assessed by combining upstream (GHRH) and secretagogue (GHS-R1a) routes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch2\u003eStack Suggestions\u003c\/h2\u003e\n\u003cp\u003eIn extended experimental designs, CJC-1295 (No-DAC) + Ipamorelin is sometimes paired with:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eGHK-Cu\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003e→ Supports skin and connective tissue regeneration\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBPC-157 + TB-500\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003e→ Complements recovery and tissue healing\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eNAD+\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003e→ Enhances mitochondrial energy metabolism and cellular recovery\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMOTS-c\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003e→ Synergizes in metabolic optimization protocols\u003cbr\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eStacks discussed are for experimental design only, not safety\/efficacy guidance.\u003c\/p\u003e\n\u003ch2\u003ePossible Side Effects\u003c\/h2\u003e\n\u003cp\u003eCJC-1295 (No-DAC) and Ipamorelin are generally observed to be well-tolerated in research, particularly Ipamorelin due to its selectivity in not raising cortisol or prolactin levels. However, as with all peptides, a range of possible side effects may be observed, particularly in the initial stages of administration or with higher doses.\u003c\/p\u003e\n\u003cp\u003eInjection Site Reactions: The most common adverse reactions are typically localized to the administration site. These may include mild pain, redness, irritation, or swelling immediately following the subcutaneous injection. These reactions are usually transient and often decrease with continued administration. Proper rotation of injection sites is a key guideline to minimize this occurrence.\u003c\/p\u003e\n\u003cp\u003eWater Retention (Edema): Increased Growth Hormone (GH) levels can sometimes lead to the body holding onto extra fluid, which may result in temporary bloating or mild swelling in the extremities. This effect is manageable but may be more pronounced in initial weeks.\u003c\/p\u003e\n\u003cp\u003eHeadaches or Flushing: Some subjects report mild to moderate headaches, which may be related to fluctuations in GH and blood flow. A warm sensation or flushing of the face and neck is also a reported side effect, often occurring shortly after injection and subsiding within minutes.\u003c\/p\u003e\n\u003cp\u003eTingling or Numbness (Paresthesia): Changes in GH and IGF-1 can occasionally lead to a sensation of tingling, often in the hands or feet. This symptom is typically mild and is a known effect associated with GH elevation.\u003c\/p\u003e\n\u003cp\u003eDizziness or Hyperactivity: Less than 1 percent of patients report dizziness or a feeling of mild hyperactivity shortly after administration.\u003c\/p\u003e\n\u003cp\u003eIt is important to emphasize that most observed side effects are temporary and mild. Research protocols must include careful monitoring and adherence to recommended dosage to ensure safety and manage any adverse reactions.\u003c\/p\u003e\n\u003ch2\u003eScientific References\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/academic.oup.com\/jcem\/article-abstract\/91\/3\/799\/2843281\"\u003eProlonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults\u003c\/a\u003e — Human RCT\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/17018654\/\"\u003ePulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GHRH analog\u003c\/a\u003e — Human RCT\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC2787983\/\"\u003eActivation of the GH\/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects\u003c\/a\u003e — Human RCT\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=ipamorelin+growth+hormone+secretagogue+GHS-R1a+selective\"\u003eIpamorelin as a selective ghrelin receptor (GHS-R1a) agonist and growth hormone secretagogue (search)\u003c\/a\u003e — Human\/Preclinical\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=ghrelin+receptor+GHS-R1a+signal+transduction+calcium+PKC\"\u003eGhrelin receptor (GHS-R1a) signaling mechanisms relevant to GH secretagogues (search)\u003c\/a\u003e — In vitro\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=GHRH+receptor+somatotroph+cAMP+PKA+growth+hormone+release\"\u003eGHRH receptor signaling in pituitary somatotrophs: cAMP\/PKA and GH release (search)\u003c\/a\u003e — In vitro\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=GHRH%281-29%29+sermorelin+clinical+trial+IGF-1\"\u003eGHRH(1–29) (sermorelin) clinical studies assessing GH\/IGF-1 axis outputs (search)\u003c\/a\u003e — Human RCT\/Observational\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=growth+hormone+pulsatility+somatostatin+GHRH+feedback+model\"\u003eGH pulsatility, somatostatin\/GHRH feedback, and endocrine rhythm models (search)\u003c\/a\u003e — Review\/Human\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/downloads.regulations.gov\/FDA-2024-N-4777-0002\/attachment_7.pdf\"\u003eCJC-1295 + Ipamorelin: synergy and pharmacodynamic modelling overview (regulatory docket attachment)\u003c\/a\u003e — Preclinical\/Modeling\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/downloads.regulations.gov\/FDA-2024-N-4777-0009\/attachment_6.pdf\"\u003eCJC-1295 safety profile: subcutaneous administration in early trials (regulatory docket attachment)\u003c\/a\u003e — Human\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC7108996\/\"\u003eBeyond the androgen receptor: the role of growth hormone secretagogues including ipamorelin\u003c\/a\u003e\u003cspan\u003e \u003c\/span\u003eReview\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/dta.233\"\u003eIdentification of CJC-1295, a growth-hormone-releasing peptide, in antidoping analyses\u003c\/a\u003e\u003cspan\u003e \u003c\/span\u003eIn vitro\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/arxiv.org\/abs\/1205.4981\"\u003eHigh sensitivity mass spectrometric quantification of serum growth hormone: implications for GHRH analogs\u003c\/a\u003e\u003cspan\u003e \u003c\/span\u003eIn vitro\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/en.wikipedia.org\/wiki\/Ipamorelin\"\u003eIpamorelin: selective agonist of the ghrelin\/GHS-R-1a receptor and growth hormone secretagogue\u003c\/a\u003e\u003cspan\u003e \u003c\/span\u003eReview\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/downloads.regulations.gov\/FDA-2024-N-4777-0002\/attachment_7.pdf\"\u003eCJC-1295 + Ipamorelin combination – FDA regulatory document\u003c\/a\u003e\u003cspan\u003e \u003c\/span\u003eRegulatory\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eCautions\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eFor educational and scientific context only; not intended to diagnose, treat, cure, or prevent any disease.\u003c\/li\u003e\n\u003cli\u003eIf you are pregnant, nursing, have a medical condition, or use prescription medication, consult a qualified professional.\u003c\/li\u003e\n\u003cli\u003eDiscontinue use if sensitivity occurs.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Peptoora","offers":[{"title":"Default Title","offer_id":61559763992906,"sku":"SB-GR-PEN-005","price":529.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0887\/1139\/7706\/files\/CJC_No_Dac_5mg_Ipamorelin_10mg.png?v=1775794383","url":"https:\/\/peptoora.com\/de\/products\/cjc-1295-no-dac-ipamorelin-5mg-10mg-pen","provider":"Peptoora LTD","version":"1.0","type":"link"}